August 24, 2021
CEO Ulrich Krasilnikoff and CSO professor Andreas Kjær presents the Interim Report First Half 2021 at HC Andersen Capital, 24 August 2021.
October 30, 2019
Curasight receives EPO patent notification with issue date 28 August 2019 and patent number 2928505
May 22, 2018
Curasight technology contribute to fluorescent tumours will vastly improve survival for people with cancer
March 1, 2018
Curasight have received US patent notification with issue date 6 February 2018 and patent number 9884131.
November 21, 2017
Curasight initiates new phase II study within Prostate Cancer for risk stratification
July 1, 2017
Ga-NOTA-AE105 (uTRACE®) included in a new book on “Novel PET Radiotracers with Potential Clinical Applications”.
April 1, 2017
Researcher from Curasight and Rigshospitalet publish review on uPAR-PET in prostate cancer.
March 1, 2017
Phase I study of our uPAR-PET tracer in the March issue of Journal of Nuclear Medicine
October 30, 2016
Our phase I study just published online in Journal of Nuclear Medicine
September 15, 2016
Curasight presents at BioPharm-America Conference in Boston.